Javascript must be enabled to continue!
Oncology Advanced Practice Provider Mentorship and Paired Clinical Research Coordinator Support to Enhance Accrual to NCI Supportive Care Trials
View through CrossRef
Background: Patient access to clinical trials has been identified as a key measure for delivery of quality cancer care. Effective recruitment and retention strategies remain an issue. Furthermore, clinical trial participants historically lack diversity. This project focused on advanced practice provider (APP) mentorship and paired clinical research support to enhance minority accrual to supportive care trials in Hawai‘i. Methods: Over a 1-year period, a formal mentorship program for six participating APPs and three clinical research coordinators (CRCs) in the Hawai‘i Minority/Underserved National Cancer Institute Community Oncology Research Program (HI M/U NCORP) was implemented. An introductory meeting kicked off the project. The APP and CRC teams then met weekly for targeted screening and accrual to supportive care trials. Monthly meetings between the mentor and teams were conducted to discuss barriers, best practices, and problem solve issues.Results: 26 unique accruals were obtained by the APP and CRC teams over the project period while increasing minority accrual. All six APPs are now actively enrolling to trials. Four of the six participating APPs are now reviewing protocols for the HI M/U NCORP for feasibility and scientific merit. Eight of the nine participating APPs and CRCs found the intervention to be acceptable and feasible. Conclusions: Mentorship of APP and CRC teams can be a successful strategy in increasing accrual and participation of APPs in clinical trial activities. Measuring minority accrual based on this strategy is more complex and dependent on the APP location, clinical trial portfolio, APP patient panel and clinical interest, as well as the expertise of the APP.
Harborside Press, LLC
Title: Oncology Advanced Practice Provider Mentorship and Paired Clinical Research Coordinator Support to Enhance Accrual to NCI Supportive Care Trials
Description:
Background: Patient access to clinical trials has been identified as a key measure for delivery of quality cancer care.
Effective recruitment and retention strategies remain an issue.
Furthermore, clinical trial participants historically lack diversity.
This project focused on advanced practice provider (APP) mentorship and paired clinical research support to enhance minority accrual to supportive care trials in Hawai‘i.
Methods: Over a 1-year period, a formal mentorship program for six participating APPs and three clinical research coordinators (CRCs) in the Hawai‘i Minority/Underserved National Cancer Institute Community Oncology Research Program (HI M/U NCORP) was implemented.
An introductory meeting kicked off the project.
The APP and CRC teams then met weekly for targeted screening and accrual to supportive care trials.
Monthly meetings between the mentor and teams were conducted to discuss barriers, best practices, and problem solve issues.
Results: 26 unique accruals were obtained by the APP and CRC teams over the project period while increasing minority accrual.
All six APPs are now actively enrolling to trials.
Four of the six participating APPs are now reviewing protocols for the HI M/U NCORP for feasibility and scientific merit.
Eight of the nine participating APPs and CRCs found the intervention to be acceptable and feasible.
Conclusions: Mentorship of APP and CRC teams can be a successful strategy in increasing accrual and participation of APPs in clinical trial activities.
Measuring minority accrual based on this strategy is more complex and dependent on the APP location, clinical trial portfolio, APP patient panel and clinical interest, as well as the expertise of the APP.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Background A major challenge for randomized phase III oncology trials is the frequent low rates of patient enrollment, resulting in high rates of premature closure due to insuffici...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
PURPOSE The National Cancer Institute (NCI)–Designated Cancer Centers (NDCCs) are active in global oncology research and training, leading collaborations that contribute to the evi...
Improving Rural Health Through Telehealth-Guided Provider-to-Provider Communication
Improving Rural Health Through Telehealth-Guided Provider-to-Provider Communication
Objectives. To assess the use, effectiveness, and implementation of telehealth-supported provider-to-provider communication and collaboration for the provision of healthcare servic...
Towards more goal-oriented care through care coordination and care planning.
Towards more goal-oriented care through care coordination and care planning.
The increasing aging of our society is putting increasing pressure on the current organization of care and support. This moved the Flemish government to a thorough reform of primar...

